OPDP Issues Untitled Letters to Pfizer and Arog Pharmaceuticals

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

OPDP Issues Untitled Letters to Pfizer and Arog Pharmaceuticals

J.W. Schomisch

June 29, 2018 at 02:18 PM EST

In the space of two weeks, CDER’s Office of Prescription Drug Promotion (OPDP) issued two Untitled Letters to Pfizer Inc. and Arog Pharmaceuticals for alleged promotional violations. A June 19 letter to Pfizer concerned a direct-to-consumer video for its Estring (estradiol vaginal ring). A June 28 letter to Arog concerned exhibit and website promotion of an investigational pro... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

OPDP Issues Untitled Letters to Pfizer and Arog Pharmaceuticals

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT